NDAORALSOLUTION
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
TEZRULY (terazosin) by Agepha Pharma. Approved for benign prostatic hyperplasia. First approved in 2024.
Drug data last refreshed Yesterday
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (2)
A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin
Started Apr 2011
24 enrolled
Ejaculation
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin
Started Mar 2007
23 enrolled
Hyperhidrosis
Company
Worked on TEZRULY at Agepha Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.